Registry of Lobbyists
| Organization: | Cystic Fibrosis Canada/Fibrose kystique Canada |
| Associated registration: | 939590-266824-25 |
| Communication date: | 2022-03-17 |
| Posted date: | 2022-04-04 |
| Designated Public Office Holders who participated in the communication: |
Michelle Boudreau,
Executive Director
Office of Pharmaceutical Management Strategies, Health Canada (HC) |
| Subject Matter of the communication: | Health |
| Communication report replaced on: | 2022-04-04 amended entry: 266824-527481 |
| Responsible Officer who filed this communication report: | Kelly Grover |
| As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed. | |